Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
PPLPHARMANSE
Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 7% | 8% | -3% |
| - | - | - | -458% |
| - | - | 31% | 16% |
| 3% | 0% | -1% | -4% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
PPLPHARMA
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,769.9 | ₹424202 Cr | 38.68 | 8.29 | 58.23 | ₹11479 Cr |
| 10,064 | ₹264141 Cr | 90.3 | 34.04 | 128.41 | ₹2568 Cr |
| 4,650 | ₹174402 Cr | 82.11 | 14.04 | 106.21 | ₹2163 Cr |
| 2,323 | ₹126811 Cr | 94.64 | 8.17 | 33.94 | ₹889 Cr |
| 1,240.6 | ₹123685 Cr | 27.41 | 9.42 | 62.53 | ₹5040 Cr |
| 1,368.3 | ₹111868 Cr | 39.95 | 11.08 | 59.2 | ₹4196 Cr |
| 1,396.9 | ₹111650 Cr | 38.54 | 10.86 | 52.6 | ₹3879 Cr |
| 2,475 | ₹102196 Cr | 45.57 | 17.23 | 76.26 | ₹1913 Cr |
| 1,694.5 | ₹96951 Cr | 26.11 | 17.95 | 96.84 | ₹3505 Cr |
| 2,015.9 | ₹91301 Cr | 16.51 | 30.95 | 154.35 | ₹5333 Cr |
| 233.69 | ₹31912 Cr | — | 0.04 | 5.1 | -₹326 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹2617 Cr | ₹2270 Cr | ₹2752 Cr | ₹2140 Cr | ₹2044 Cr | ₹1934 Cr | ₹2754 Cr | ₹2204 Cr | ₹2242 Cr | ₹1951 Cr | ₹2552 Cr | ₹1959 Cr | ₹1911 Cr | ₹1749 Cr | ₹2164 Cr | ₹1716 Cr | ₹1720 Cr | ₹1482 Cr | ₹2131 Cr | ₹1539 Cr | ₹1578 Cr |
| ₹36 Cr | ₹89 Cr | ₹46 Cr | ₹43 Cr | ₹66 Cr | ₹58 Cr | ₹42 Cr | ₹12 Cr | ₹61 Cr | ₹20 Cr | ₹26 Cr | ₹62 Cr | ₹49 Cr | ₹38 Cr | ₹25 Cr | ₹83 Cr | ₹46 Cr | ₹72 Cr | ₹78 Cr | ₹161 Cr | ₹18 Cr |
| ₹2653 Cr | ₹2359 Cr | ₹2798 Cr | ₹2183 Cr | ₹2109 Cr | ₹1992 Cr | ₹2796 Cr | ₹2216 Cr | ₹2303 Cr | ₹1971 Cr | ₹2579 Cr | ₹2020 Cr | ₹1961 Cr | ₹1787 Cr | ₹2188 Cr | ₹1799 Cr | ₹1766 Cr | ₹1554 Cr | ₹2210 Cr | ₹1700 Cr | ₹1595 Cr |
| ₹2501 Cr | ₹2298 Cr | ₹2510 Cr | ₹2157 Cr | ₹2088 Cr | ₹2024 Cr | ₹2436 Cr | ₹2063 Cr | ₹2092 Cr | ₹1931 Cr | ₹2219 Cr | ₹1877 Cr | ₹1830 Cr | ₹1790 Cr | ₹1997 Cr | ₹1793 Cr | ₹1714 Cr | ₹1627 Cr | ₹1899 Cr | ₹1461 Cr | ₹1519 Cr |
| ₹385 Cr | ₹285 Cr | ₹507 Cr | ₹239 Cr | ₹224 Cr | ₹165 Cr | ₹603 Cr | ₹350 Cr | ₹403 Cr | ₹224 Cr | ₹556 Cr | ₹330 Cr | ₹315 Cr | ₹171 Cr | ₹376 Cr | ₹170 Cr | ₹219 Cr | ₹89 Cr | ₹476 Cr | ₹386 Cr | ₹214 Cr |
| ₹88 Cr | ₹88 Cr | ₹83 Cr | ₹89 Cr | ₹82 Cr | ₹86 Cr | ₹104 Cr | ₹103 Cr | ₹108 Cr | ₹107 Cr | ₹114 Cr | ₹106 Cr | ₹110 Cr | ₹119 Cr | ₹104 Cr | ₹95 Cr | ₹83 Cr | ₹62 Cr | ₹57 Cr | ₹50 Cr | ₹49 Cr |
| ₹64 Cr | -₹27 Cr | ₹29 Cr | -₹104 Cr | -₹61 Cr | -₹98 Cr | ₹257 Cr | ₹50 Cr | ₹103 Cr | -₹67 Cr | ₹215 Cr | ₹5 Cr | ₹20 Cr | -₹122 Cr | ₹87 Cr | -₹89 Cr | -₹37 Cr | -₹135 Cr | ₹254 Cr | ₹189 Cr | ₹27 Cr |
| -₹13 Cr | -₹89 Cr | -₹22 Cr | -₹146 Cr | -₹114 Cr | -₹100 Cr | ₹137 Cr | -₹13 Cr | ₹5 Cr | -₹111 Cr | ₹89 Cr | -₹4 Cr | -₹14 Cr | -₹113 Cr | ₹42 Cr | -₹106 Cr | -₹48 Cr | -₹129 Cr | ₹185 Cr | ₹154 Cr | ₹20 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| — | — | — | — | — | — |
| ₹1327 Cr | ₹1324 Cr | ₹1323 Cr | ₹1193 Cr | ₹1186 Cr | ₹995 Cr |
| ₹73 Cr | ₹62 Cr | ₹27 Cr | ₹0 | ₹0 | ₹10 L |
| ₹6763 Cr | ₹6739 Cr | ₹6561 Cr | ₹5580 Cr | ₹5511 Cr | ₹4610 Cr |
| ₹6763 Cr | ₹6739 Cr | ₹6561 Cr | ₹5580 Cr | ₹5511 Cr | ₹4610 Cr |
| ₹8163 Cr | ₹8125 Cr | ₹7911 Cr | ₹6774 Cr | ₹6697 Cr | ₹5605 Cr |
| ₹4300 Cr | ₹3214 Cr | ₹2484 Cr | ₹3384 Cr | ₹2622 Cr | ₹2339 Cr |
| -₹157 Cr | -₹145 Cr | -₹157 Cr | -₹130 Cr | -₹105 Cr | -₹22 Cr |
| ₹292 Cr | ₹275 Cr | ₹286 Cr | ₹282 Cr | ₹240 Cr | ₹236 Cr |
| ₹94 Cr | ₹49 Cr | ₹32 Cr | ₹276 Cr | ₹145 Cr | ₹7 Cr |
| ₹4529 Cr | ₹3393 Cr | ₹2645 Cr | ₹3812 Cr | ₹2903 Cr | ₹2560 Cr |
| — | — | — | — | — | — |
| ₹2479 Cr | ₹1534 Cr | ₹1538 Cr | ₹1193 Cr | ₹1026 Cr | ₹918 Cr |
| ₹1479 Cr | ₹1185 Cr | ₹1576 Cr | ₹1305 Cr | ₹1243 Cr | ₹1141 Cr |
| ₹748 Cr | ₹995 Cr | ₹1171 Cr | ₹1302 Cr | ₹659 Cr | ₹361 Cr |
| ₹169 Cr | ₹137 Cr | ₹84 Cr | ₹51 Cr | ₹190 Cr | ₹172 Cr |
| ₹4875 Cr | ₹3851 Cr | ₹4369 Cr | ₹3851 Cr | ₹3118 Cr | ₹2591 Cr |
| ₹17567 Cr | ₹15369 Cr | ₹14925 Cr | ₹14437 Cr | ₹12717 Cr | ₹10756 Cr |
| ₹96 Cr | ₹100 Cr | ₹61 Cr | ₹57 Cr | ₹45 Cr | ₹30 Cr |
| ₹5495 Cr | ₹4720 Cr | ₹4559 Cr | ₹5505 Cr | ₹4023 Cr | ₹2910 Cr |
| — | — | — | — | — | — |
| ₹14905 Cr | ₹13118 Cr | ₹12138 Cr | ₹10842 Cr | ₹9510 Cr | ₹8173 Cr |
| ₹6214 Cr | ₹4984 Cr | ₹4148 Cr | ₹3374 Cr | ₹2631 Cr | ₹2068 Cr |
| ₹7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹8684 Cr | ₹8133 Cr | ₹7990 Cr | ₹7469 Cr | ₹6879 Cr | ₹6105 Cr |
| ₹799 Cr | ₹489 Cr | ₹566 Cr | ₹853 Cr | ₹673 Cr | ₹400 Cr |
| ₹305 Cr | ₹271 Cr | ₹240 Cr | ₹212 Cr | ₹217 Cr | ₹123 Cr |
| ₹305 Cr | ₹271 Cr | ₹240 Cr | ₹212 Cr | ₹217 Cr | ₹123 Cr |
| ₹155 Cr | ₹91 Cr | ₹115 Cr | ₹494 Cr | ₹297 Cr | ₹152 Cr |
| ₹15 Cr | ₹15 Cr | ₹0 | ₹4 L | ₹4 L | ₹4 L |
| ₹10259 Cr | ₹9487 Cr | ₹9461 Cr | ₹9593 Cr | ₹8565 Cr | ₹7007 Cr |
| — | — | — | — | — | — |
| ₹132 Cr | ₹20 Cr | ₹145 Cr | ₹427 Cr | ₹50 Cr | ₹0 |
| ₹3064 Cr | ₹2313 Cr | ₹2176 Cr | ₹1681 Cr | ₹1389 Cr | ₹1232 Cr |
| ₹2158 Cr | ₹2350 Cr | ₹2134 Cr | ₹1799 Cr | ₹1785 Cr | ₹1575 Cr |
| ₹1224 Cr | ₹501 Cr | ₹483 Cr | ₹308 Cr | ₹329 Cr | ₹406 Cr |
| ₹145 Cr | ₹135 Cr | ₹82 Cr | ₹140 Cr | ₹94 Cr | ₹141 Cr |
| ₹586 Cr | ₹563 Cr | ₹445 Cr | ₹488 Cr | ₹505 Cr | ₹396 Cr |
| ₹7308 Cr | ₹5881 Cr | ₹5464 Cr | ₹4843 Cr | ₹4152 Cr | ₹3749 Cr |
| ₹2433 Cr | ₹2031 Cr | ₹1095 Cr | ₹992 Cr | ₹1034 Cr | ₹1158 Cr |
| ₹17567 Cr | ₹15369 Cr | ₹14925 Cr | ₹14437 Cr | ₹12717 Cr | ₹10756 Cr |
| ₹61 | ₹61 | ₹60 | ₹57 | ₹56 | ₹56 |
| ₹61 | ₹61 | ₹60 | ₹55 | ₹55 | ₹55 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| -₹233 Cr | ₹342 Cr | ₹120 Cr | -₹161 Cr | ₹441 Cr | ₹884 Cr |
| ₹1569 Cr | ₹1373 Cr | ₹1276 Cr | ₹1136 Cr | ₹787 Cr | ₹478 Cr |
| ₹527 Cr | -₹488 Cr | -₹234 Cr | -₹302 Cr | -₹292 Cr | -₹620 Cr |
| ₹1863 Cr | ₹1227 Cr | ₹1161 Cr | ₹673 Cr | ₹936 Cr | ₹742 Cr |
| ₹1653 Cr | ₹892 Cr | ₹1005 Cr | ₹484 Cr | ₹766 Cr | ₹598 Cr |
| -₹826 Cr | -₹477 Cr | -₹434 Cr | -₹1339 Cr | -₹1812 Cr | -₹4480 Cr |
| -₹39 Cr | -₹441 Cr | -₹422 Cr | ₹818 Cr | ₹794 Cr | ₹3977 Cr |
| ₹788 Cr | -₹26 Cr | ₹148 Cr | -₹37 Cr | -₹251 Cr | ₹94 Cr |
| ₹182 Cr | ₹219 Cr | ₹53 Cr | ₹85 Cr | ₹262 Cr | ₹152 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹77 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹11 Cr |
| ₹6 Cr | -₹11 Cr | ₹18 Cr | ₹5 Cr | -₹2 Cr | ₹4 Cr |
| ₹976 Cr | ₹182 Cr | ₹219 Cr | ₹53 Cr | ₹85 Cr | ₹262 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 5 out of 9 oscillators
RSI
67.21Buy
STOCH %K
83.65Sell
MACD Level(12,26)
7.62Buy
Ultimate Oscillator
65.44Buy
Aroon Oscillator
12.00Sell
BOP
-0.64Sell
CCI
144.93Sell
Williams %R
-16.35Sell
Momentum
37.68Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
222.50Buy
SMA 9
217.34Buy
EMA 21
212.39Buy
SMA 21
205.34Buy
EMA 50
206.45Buy
SMA 50
208.81Buy
EMA 200
190.75Buy
SMA 200
177.63Buy
WMA 20
212.38Buy
Pivot
Pivot
Classic
Resistance 5
274.52
Resistance 4
265.68
Resistance 3
256.84
Resistance 2
248.00
Resistance 1
243.96
Pivot
239.16
Support 1
235.12
Support 2
230.32
Support 3
221.48
Support 4
212.64
Support 5
203.80
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 34.80% | 34.80% | 34.86% | 34.86% | 34.86% | 34.86% |
| 13.65% | 12.51% | 30.17% | 29.66% | 30.27% | 30.86% |
| 1.72% | 1.39% | 1.49% | 1.66% | 1.78% | 1.93% |
| 12.71% | 13.18% | 14.12% | 14.03% | 13.11% | 12.32% |
| 37.12% | 38.12% | 19.36% | 19.79% | 19.98% | 20.03% |
Bulk & block deals
Name
Graviton Research Capital Llp
Graviton Research Capital Llp
East Bridge Capital Master Fund Limited
East Bridge Capital Master Fund I Limited
East Bridge Capital Master Fund Limited
East Bridge Capital Master Fund I Limited
Caisse De Depot Et Placement Du Quebec
The Vanguard Group Inc Ac Vanguard Total International Stock Index Fund
Ishares Core Emerging Markets Mauritius Co
Ishares Core Msci Emerging Markets Etf
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 20 Feb 2025 | Purchase | 150.65 Cr | ₹219.70 | 68.57 L | Bulk | 0.515852 | NSE |
| 20 Feb 2025 | Sell | 150.77 Cr | ₹219.88 | 68.57 L | Bulk | 0.515852 | NSE |
| 31 Oct 2023 | Sell | 345.85 Cr | ₹102.80 | 3.36 Cr | Block | 2.526995 | BSE |
| 31 Oct 2023 | Purchase | 345.85 Cr | ₹102.80 | 3.36 Cr | Block | 2.526995 | BSE |
| 31 Oct 2023 | Sell | 345.85 Cr | ₹102.80 | 3.36 Cr | Bulk | 2.526995 | BSE |
| 31 Oct 2023 | Purchase | 345.85 Cr | ₹102.80 | 3.36 Cr | Bulk | 2.526995 | BSE |
| 16 Jun 2023 | Sell | 99.87 Cr | ₹94.48 | 1.06 Cr | Bulk | 0.793967 | NSE |
| 16 Jun 2023 | Purchase | 58.75 Cr | ₹94.71 | 62.03 L | Bulk | 0.465912 | NSE |
| 03 Nov 2022 | Sell | 67.63 Cr | ₹166.95 | 40.51 L | Block | 0.304256 | BSE |
| 03 Nov 2022 | Purchase | 67.63 Cr | ₹166.95 | 40.51 L | Block | 0.304256 | BSE |
Insider trading & SAST
Client name
Hdfc Mutual Fund
Hdfc Mutual Fund
East Bridge Capital Master Fund I Ltd & East Bridge Capital Master Fund
Hdfc Mutual Fund
Hdfc Mutual Fund
Ajay G Piramal & Others
Ajay G Piramal & Others
Caisse De Depot Et Placement Du Quebec
Deutsche Bank Ag, Singapore Branch , Dbx Advisors Llc
Deutsche Bank Ag, Singapore Branch, Dbx Advisors Llc
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 06 Aug 2026 | Other | Disposal | 2 | 7.01 | 0 | — | 2.67 Cr | 14 Jul 2026 | Market | 9,33,93,655 | SAST | 29(2) | — |
| 10 Jul 2025 | Other | Acquisition | 1.99 | 9.03 | 0 | — | 2.65 Cr | 26 Jun 2025 | Market | 12,00,82,126 | SAST | 29(2) | — |
| 09 Oct 2024 | Other | Disposal | 0.17 | 3.6 | 0 | — | 21.99 L | 06 Sep 2024 | Market | 4,77,72,918 | SAST | 29(2) | — |
| 02 Aug 2024 | Other | Acquisition | 2.06 | 7.06 | 0 | — | 2.73 Cr | 29 Jul 2024 | Market | 9,35,33,550 | SAST | 29(2) | — |
| 19 Mar 2024 | Other | Acquisition | 0.06 | 5.01 | 0 | — | 8.21 L | 14 Mar 2024 | Market | 6,62,51,434 | SAST | 29(1) | — |
| 06 Sep 2023 | Promoter | Acquisition | 37.2 | 35.02 | 0 | — | 4.82 Cr | 23 Aug 2023 | Rights Issue | 46,33,31,304 | SAST | 29(1) | — |
| 06 Sep 2023 | Promoter | Acquisition | 37.2 | 35.02 | 0 | — | 4.82 Cr | 23 Aug 2023 | Rights Issue | 46,33,31,304 | SAST | 29(2) | — |
| 06 Jun 2023 | Other | Disposal | 0.17 | 3.54 | 0 | — | 20.14 L | 29 May 2023 | Market | 4,22,97,333 | SAST | 29(2) | — |
| 17 Nov 2022 | Other | Acquisition | — | — | 0 | — | 46 K | 19 Oct 2022 | Encumbrance Shares | 45,996 | SAST | 29(1) | — |
| 17 Nov 2022 | Other | Acquisition | 20 | 20 | 0 | — | 23.87 Cr | 19 Oct 2022 | Encumbrance Shares | 23,86,63,700 | SAST | 29(1) | — |
Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
Piramal Pharma (PPL) is one of the India’s largest Pharmaceutical Company. PPL offers a portfolio of differentiated products and services through its global development and manufacturing facilities and a global
Corporate Actions
Date
Type
Details
Company details
Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Piramal Pharma Share Price
233.69-6.23 (-2.60%)
+17.06% past 1 Year
News
Piramal Pharma Expects EBITDA Margins To Improve In Second Half
Equity
PPLPHARMA
Piramal Pharma Reports Strong Second Quarter EBITDA Growth And Margin Expansion
Equity
PPLPHARMA
Piramal Pharma Reports Q2 Consolidated Profit Against Prior Year Loss
Equity
PPLPHARMA
Piramal Pharma Reports Strong Q2 Revenue Growth And Returns To Profit
Equity
PPLPHARMA
Piramal Pharma Bayer Sales Arrangement Ends December 31 2026 Without Renewal
Equity
PPLPHARMA
Piramal Pharma UK Morpeth plant gets seven US FDA observations post inspection
Equity
PPLPHARMA
Piramal Pharma NSE block trade of Rs 15.12 crores at Rs 223.51
Equity
PPLPHARMA
Piramal Pharma raises stake in Yapan Bio, makes it a subsidiary
Equity
PPLPHARMA
Piramal Pharma, Carlyle selldown cancellation reported by IIFL
Equity
PPLPHARMA
Piramal Pharma sees Rs 29.81 crores NSE block trade at Rs 205.01
Equity
PPLPHARMA
Piramal Pharma Restarts Ahmedabad Operations After Flood Disruption
Equity
PPLPHARMA
Goldman Sachs reiterates Buy on Piramal Pharma with Rs 250 target
Equity
PPLPHARMA
Piramal Pharma maintains steady capex guidance with Lexington project on schedule
Equity
PPLPHARMA
Piramal Pharma highlights elevated effective tax rate during current fiscal scale-up
Equity
PPLPHARMA
Piramal Pharma reiterates full-year guidance for complex hospital generics
Equity
PPLPHARMA
Piramal Pharma maintains existing guidance, potential update after September quarter
Equity
PPLPHARMA
Piramal Pharma management reiterates full-year CDMO revenue guidance on concall
Equity
PPLPHARMA
Piramal Pharma reiterates FY30 target of 25 percent EBITDA margin
Equity
PPLPHARMA
Piramal Pharma maintains FY27 capex guidance at Rs 12-13.5 crores
Equity
PPLPHARMA
Piramal Pharma guides for EBITDA margin expansion on overseas growth visibility
Equity
PPLPHARMA